Lindsay E. Clegg

Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the EXSCEL and SAVOR‐TIMI 53 cardiovascular outcomes trials

R. Holman, Adrian F. Hernandez, J. Vora, 2021, Diabetes, obesity & metabolism.

Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial

R. Holman, Adrian F. Hernandez, H. Heerspink, 2019, Cardiovascular Diabetology.

Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL

R. Holman, Adrian F. Hernandez, H. Heerspink, 2018, Diabetes Care.

Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial)

Deepak L. Bhatt, B. Scirica, I. Raz, 2021, PloS one.

Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL

R. Holman, G. Bakris, Adrian F. Hernandez, 2020, Diabetes, obesity & metabolism.

Effect of once‐weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial

R. Holman, H. Heerspink, D. Boulton, 2020, Diabetes, obesity & metabolism.